Complejo Asistencial Universitario de Burgos-ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2022

  1. Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program

    Oncotarget, Vol. 13, Núm. 1, pp. 812-827

2021

  1. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

    BMC Cancer, Vol. 21, Núm. 1

1997

  1. Experience of oncopaz cooperative group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast

    Oncology (Switzerland), Vol. 54, Núm. 1, pp. 30-37

1996

  1. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin: A phase II study of the ONCOPAZ Cooperative Group

    Cancer, Vol. 78, Núm. 2, pp. 211-216

1995

  1. Treatment of advanced gastric cancer with the combination fluorouracil, leucovorin, etoposide, and cisplatin: a phase II study of the ONCOPAZ cooperative group

    Cancer Chemotherapy and Pharmacology, Vol. 36, Núm. 3, pp. 255-258

1994

  1. Comparison of two chemotherapeutic regimens - mitomycin + vindesine 4-cisplatin (MVP) vs. mitomycin + ifosfamide + cisplatin (MIP) - in advanced non-small-cell lung cancer

    Annals of Oncology, Vol. 5, Núm. 4, pp. 323-327